Fighting for market share, J&J expects last year's copycat pain to 'bleed into 2020'

Amid launches and fierce fights for share in key markets, several Johnson & Johnson meds scored some wins against generic and biosimilar competition last year. But now that it's 2020, that success is proving to be a double-edged sword.

“As we sat here last year, we would’ve expected a bigger impact from [losses of exclusivity],” J&J’s chief financial Joe Wolk said on Wednesday’s fourth-quarter 2019 conference call.